VIFORFRANCE clinical trials
Acquired by CSL Limited, Aug 9, 2022 · source ↗
The registry lists 6 studies whose lead sponsor is VIFORFRANCE. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 16, 2021.
Before and after it joined CSL Limited
- First submitted before VIFORFRANCE became part of CSL Limited
- 6
- First submitted after VIFORFRANCE became part of CSL Limited
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- VIFORFRANCE6 studies
Something wrong with this grouping? Tell us on the CSL Limited page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All CSL Limited studies →
- Study of the Prevalence of Iron Deficiency in Patients With Scheduled Major Surgery (CARENFER PBM)Status unknownNCT04800042Not applicable
Sponsor listed in the registry: VIFORFRANCE · First submitted before VIFORFRANCE became part of CSL Limited
- Study of the Prevalence of Iron Deficiency in Patients With Chronic Renal Failure But Non-Dialysis (CARENFER IRC-ND)Status unknownNCT04123145Not applicable
Sponsor listed in the registry: VIFORFRANCE · First submitted before VIFORFRANCE became part of CSL Limited
- Study of the Prevalence of Iron Deficiency in Patients With Chronic Inflammatory Bowel DiseaseStatus unknownNCT04123990Not applicable
Sponsor listed in the registry: VIFORFRANCE · First submitted before VIFORFRANCE became part of CSL Limited
- Study of the Prevalence of Iron Deficiency in Patients With Heart FailureStatus unknownNCT03924258Not applicable
Sponsor listed in the registry: VIFORFRANCE · First submitted before VIFORFRANCE became part of CSL Limited
- Prevalence Study of Iron Deficiency in Patients With CancerStatus unknownNCT03924271Not applicable
Sponsor listed in the registry: VIFORFRANCE · First submitted before VIFORFRANCE became part of CSL Limited
- Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer PatientsStatus unknownNCT03831633Phase 4
Sponsor listed in the registry: VIFORFRANCE · First submitted before VIFORFRANCE became part of CSL Limited